🔗 Share this article TikTok Content Creators Fueling Unofficial Trade for Unapproved Slimming Medication An underground economy for unapproved weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, according to new investigations. Investigational Treatment Acquiring Traction Online Retatrutide, which is still in research studies, is being advertised by online personalities for its supposed weight-reducing properties. Followers are encouraged to contact these accounts privately for supplier links, while also receiving promotional offers. Thriving Trade on Social Networks Additionally, a flourishing market exists on Telegram, where communities with thousands of participants share “before and after” images, injection guides and assertions of rapid UK delivery. Vendors promote the substance there before directing customers to WhatsApp for transactions. Understanding Retatrutide Retatrutide is an investigational injection created by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could help patients reduce up to 25% of their total weight. Nicknamed the “triple G”, the substance is being promoted digitally as the next Ozempic. Medical Professionals Voice Concerns However, physicians and chemists have warned that the distribution of what is still an unapproved drug in the UK is a cause for concern and could lead to individuals injecting substances of uncertain source. Several experts said the demand for retatrutide could be linked to the rising price of licensed slimming products such as Mounjaro. Legal Position and Enforcement Selling retatrutide on social media or messaging apps is illegal in the UK, as it is an unapproved drug that cannot be marketed or distributed for personal consumption under the Human Medicines Regulations 2012. Several influencers try to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and distribution can still violate pharmaceutical, advertising, and consumer laws, risking penalties, prosecution or prison. Service Reaction and Material Elimination Based on the social media company, the platform has taken down violative content and prohibited related hashtags and query recommendations. The company said it was dedicated to maintaining the platform safe and allocating resources in enhancing enforcement strategies. Digital Marketplace Operations Investigations also found communities with up to 9,000 members selling the experimental drug using Telegram's integrated discovery tool, which operates like a public directory. Typing “retatrutide” instantly brings up groups with numerous of members, populated with photos of slimming results, glowing testimonials and detailed instructions for mixing or administering at home. Within minutes of joining one group, a seller posted WhatsApp details, where the majority of purchases take place. The seller sent an instruction manual and promised shipping within 48 hours. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another provided a photo of a alleged testing documentation. None inquired about body mass, medical conditions or past usage. Item Details and Pricing Inside these communities, messages show dark colored parcels with postal service labels, claiming to contain new batches. One communication read: “It took eight of us to load them this morning.” Customers can select between dry substance containers, prepared at residence with purified liquid, or pre-filled injectors usually priced at £160 for 20mg. When questioned how long a injector should be used, sellers give conflicting responses ranging from a few weeks to “depends on your body”. Platform Oversight and Safety Measures A spokesperson for the messaging service said it actively moderated dangerous material on its service including material that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”. Medical Professional Warnings “People are administering materials they can’t verify. Even if the science behind this drug is sound, these digital versions may not contain what they claim,” said a pharmacy expert, the director of pharmacy at a pharmacy service. Dr Crystal Wyllie of an online medical service linked the surge in demand to current cost increases for authorized slimming drugs such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But fake injections are highly risky. You cannot know what’s inside or whether the environment they were produced in was sterile,” she said. Her team has already encountered individuals injured by self-injection from unconfirmed sources. “We understand the frustration, but buying from messaging apps or WhatsApp is taking chances with your well-being,” stated the doctor. “These substances could be contaminated or incorrectly dosed.” Manufacturer Statement A representative from Eli Lilly said the substance was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Consequently at this time no one can market [it] for personal consumption,” they explained, noting that any product “misleadingly claiming itself as a company investigational substance not yet approved … may expose patients to potentially serious medical dangers”.